PHATHOM PHARMACEUTICALS, INC. Total Liabilities
PHATHOM PHARMACEUTICALS, INC. (PHAT) had Total Liabilities of $671.35 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-07-30
- 2026-06-30: Liabilities $671.35M.
- 2026-03-31: Liabilities $642.08M.
- 2025-12-31: Liabilities $697.32M.
- 2025-09-30: Liabilities $662.82M.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $671.35M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $642.08M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $697.32M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $662.82M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $656.05M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $632.58M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $631.90M 10-K · filed 2026-02-26 |
| 2024-09-30 | $574.16M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $553.21M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $505.00M 10-Q/A · filed 2024-06-14 |
| 2023-12-31 | $486.60M 10-K · filed 2025-03-06 |
| 2023-09-30 | $254.76M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $247.44M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $234.21M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $239.62M 10-K/A · filed 2024-06-14 |
| 2022-09-30 | $228.35M 10-Q/A · filed 2022-11-09 |
| 2022-06-30 | $220.50M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $111.01M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $117.28M 10-K · filed 2023-02-28 |
| 2021-09-30 | $124.90M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $82.45M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $82.02M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $100.84M 10-K · filed 2022-03-01 |
| 2020-09-30 | $74.50M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $64.00M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $55.22M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $29.22M 10-K · filed 2021-03-30 |
| 2019-09-30 | $232.17M 10-Q · filed 2019-11-25 |
| 2018-12-31 | $2.19M 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |